InSilico Medicine Hong Kong Limited
Reserved
The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
Insilico Medicine developed an AI platform which allows for rapid identification of new molecular targets using multi-omics data and rapid generation of novel compounds using AI. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Technology Innovation Award. The company is betting on the innovative pharmaceutical industry in Greater China and established the HQ in Hong Kong and R&D offices in Taipei. It has a close collaboration with the greatest research platform, WuXi AppTec on synthetic chemistry. Its goal is to help the Chinese pharmaceutical companies leapfrog years of pharmaceutical R&D using next-generation AI and provide novel disease-relevant targets and novel small molecules for these targets. This strategy is aligned with the new policy of the Chinese government intended to foster and promote the creation of innovative medicine in China.
Pandomics.com
Insilico Medicine developed Pandomics, a bioinformatics and AI platform which allows for rapid identification of new molecular targets using multi-omics data and rapid generation of novel compounds using AI - https://pandomics.com/
Insilico uses artificial intelligence for drug discovery, biomarker development and aging research.